Study of Tumor Tissue Samples From Patients With Stage I, Stage II, or Stage III Malignant Melanoma

Case Comprehensive Cancer Center (Case CCC)

Status: Terminated

Conditions: Melanoma (Skin)

Treatments: Genetic: polymorphism analysis; Other: medical chart review; Other: matrix-assisted laser desorption/ionization time of flight mass spectrometry; Genetic: polymerase chain reaction; Genetic: gene expression analysis

Study type: Observational

Funder types: Other; NIH

Identifiers

NCT00991991

P30CA043703 (U.S. NIH Grant/Contract)

CASE 1609-CC733 (Other Identifier)

CASE1609 (Other Identifier)

Details and patient eligibility

About

RATIONALE: Studying the genes expressed in samples of tumor tissue from patients with cancer may help doctors identify biomarkers related to cancer.

PURPOSE: This research study is looking at tumor tissue samples from patients with stage I, stage II, or stage III malignant melanoma.

Full description

OBJECTIVES:

• Determine the genetic profile of primary melanomas with and without synchronous regional nodal involvement by examining for 1) activating mutations B-Raf and N-Ras associated with melanoma development, and 2) allelic imbalances across the genome.
• Compare the genetic profile of primary melanomas from patients with and without lymph node involvement.
• Determine the combinations of genetic lesions that correlate with nodal metastasis by adopting a statistical machine learning approach to build a lesion-based classifier for nodal metastasis.

OUTLINE: Laser capture microdissection is performed on the archived tissue samples to isolate melanoma cells. DNA is then purified from the samples and amplified using PCR. Matrix-assisted laser desorption/ionization (MALDI)-time of flight mass spectrometry technology is used to detect mutations of B-Raf and N-Ras. Single nucleotide polymorphism arrays are also performed.

Information about the patient's demographics (e.g., TNM staging, sex, age, and tissue collection dates) will be gathered by chart review or from the Multidisciplinary Melanoma Conference at University Hospitals tumor conference report in order to match cases.

Enrollment: 5 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Node positive Group (experimental group)

  • Primary melanoma > 2 mm in depth
  • Metastasis must be > 0.1 mm and detectable by IHC or hematoxylin and eosin (H&E) to be considered node positive
  • Slides and block for primary and node must be archived in UH dermatopathology

• Node Negative Group (control group)

  • Primary melanoma > 2 mm in depth

  • A negative sentinel lymph node must be negative by IHC and H&E

    • No stage IV disease
    • No acral and mucosal histology
    • No history of prior invasive melanoma
    • Underwent primary excision and sentinel lymph node biopsy within 3 months of each other
    • Archived tissue available

  • Slides and block for primary tumor and node biopsy must be archived in University Hospitals Case Medical Center (UH) dermatopathology

Exclusion criteria

• Acral and mucosal histology
• Previous diagnosis of invasive melanoma
• previous chemotherapy or immunotherapy
• patients who are found to have stage IV disease during workup